PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)

Import this data to Google Sheets with:

=jivedata("PVCT","financials")

Full statements spill as a table. For one cell: =jivedata("PVCT","Revenue") or =jivedata("PVCT","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

PROVECTUS BIOPHARMACEUTICALS, INC.

PVCT • CIK 0000315545

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$557.71	$617.14	$336.108	$336.108
Operating Income (Loss)	$-2,901.25	$-4,532.384	$-5,294.765	$-4,582.677
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	—	$-4,762.137	$-5,505.124	$-4,781.106
Net Income (Loss) Attributable to Noncontrolling Interest	—	$-29.585	$-74.273	$-31.763
Net Income (Loss) Attributable to Parent	$-3,101.768	$-4,732.552	$-5,430.851	$-4,749.343
Weighted Average Number of Shares Outstanding, Basic	419,508,146	419,810,059	420,279,879	420,279,879
Research and Development Expense	$1,749.24	$1,999.127	$1,897.276	$1,105.585
General and Administrative Expense	$1,709.72	$3,150.397	$3,733.597	$3,477.092
Operating Expenses	$3,458.96	$5,149.524	$5,630.873	$4,582.677
Interest Income (Expense), Net	$-216.214	$-239.073	$-210.359	$-210.359
Nonoperating Income (Expense)	$-200.518	$-229.753	$-210.359	$-198.429

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$12.02	$4.863	$3	$2.068
Operating Lease, Right-of-Use Asset	$72.026	$24.624	$126.628	$102.549
Assets	$1,448.843	$1,006.259	$697.502	$1,473.501
Liabilities	$9,042.194	$6,975.484	$7,000.22	$7,761.065
Cash	$76.576	$307.442	$251.291	$1,156.915
Restricted Cash, Current	$950.223	$182.284	$182.284	$30.542
Prepaid Expense and Other Assets, Current	$337.522	$487.046	$316.583	$211.969
Assets, Current	$1,364.797	$976.772	$567.874	$1,368.884
Accounts Payable, Current	$1,675.891	$1,106.551	$716.22	$931.972
Deferred Revenue, Current	$953.248	$336.108	$336.108	$57.48
Interest Payable, Current	$22.6	—	—	$22.6
Other Accrued Liabilities, Current	$3,240.436	$2,175.376	$3,161.379	$3,159.127
Notes Payable to Bank, Current	$277.815	$206.463	$217.772	$92.443
Convertible Notes Payable, Current	$800	—	—	$800
Operating Lease, Liability, Current	$48.077	$25.299	$48.083	$49.98
Liabilities, Current	$9,016.895	$6,975.484	$6,897.378	$7,707.145
Notes Payable, Noncurrent	—	—	$23.621	$23.621
Operating Lease, Liability, Noncurrent	$25.299	$25.299	$79.221	$53.92
Common Stock, Value, Issued	$419.522	$420.28	$420.28	$420.28
Additional Paid in Capital	$244,714.967	$251,090.027	$256,179.846	$258,475.479
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-60.165	$-60.741	$-60.191	$-59.803
Retained Earnings (Accumulated Deficit)	$-252,690.409	$-257,422.961	$-262,853.812	$-265,126.832
Stockholders' Equity Attributable to Parent	$-7,593.351	$-5,959.332	$-6,298.737	$-6,275.171
Stockholders' Equity Attributable to Noncontrolling Interest	—	$-9.893	$-3.981	$-12.393
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	—	$-5,969.225	$-6,302.718	$-6,287.564
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$110.994	$118.151	$120.013	$120.945
Preferred Stock, Shares Authorized	25,000,000	25,000,000	25,000,000	25,000,000
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	419,522,119	420,279,879	420,279,879	420,279,879

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	—	$-4,762.137	$-5,505.124	$-4,781.106
Net Cash Provided by (Used in) Operating Activities	$-2,571.978	$-3,284.091	$-3,325.991	$-2,425.234
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$-24.485	$-0.847	$0.55	$0.496
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-404.908	$-537.073	$-238.435	$740.444
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$1,026.799	$489.726	$251.291	$5.72
Cash and Cash Equivalents, at Carrying Value	$76.576	$307.442	$251.291	$84.739
Restricted Cash	$950.223	$182.284	$182.284	$-346.876
Share-based Payment Arrangement, Noncash Expense	$2.85	$1,280.776	$1,237.546	$1,212.371
Proceeds from Convertible Debt	$800	$853	$870	$2,075
Proceeds from Related Party Debt	$1,675	$2,000	$1,640	$985
Depreciation	$8.921	$7.157	$1.863	$1.863
Repayments of Notes Payable	$283.445	—	$272.994	$269.818
Repayments of Related Party Debt	—	$100	$100	$100
Net Cash Provided by (Used in) Financing Activities	$2,191.555	$2,747.865	$3,087.006	$3,165.182
Interest Paid, Excluding Capitalized Interest, Operating Activities	—	—	$4.305	$2.972
Increase (Decrease) in Receivables	$0.082	$-0.476	$-0.476	$-0.476
Increase (Decrease) in Prepaid Expense and Other Assets	$-451.425	$-84.247	$-478.387	$-247.803
Increase (Decrease) in Accounts Payable, Trade	$-418.37	$-569.157	$-390.331	$-379.067
Increase (Decrease) in Deferred Revenue	$-557.71	$-617.14	$-336.108	$-336.108
Increase (Decrease) in Interest Payable, Net	$205.655	$225.481	$201.772	$193.279
Increase (Decrease) in Other Accrued Liabilities	$836.426	$1,066.881	$986.003	$1,078.271
IncreaseDecreaseInOperatingLeaseLiability	$-44.422	$-48.077	$-48.127	$-46.232

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("PVCT","financials")

Full statements spill as a table. For one cell: =jivedata("PVCT","Revenue") or =jivedata("PVCT","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.